よむ、つかう、まなぶ。
参考資料3 有効性評価に基づく大腸がん検診ガイドライン2024年度版 (62 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_71872.html |
| 出典情報 | がん検診のあり方に関する検討会（第46回 3／23）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
20.
27.
28.
29.
30.
91.
9グ2.
9.
Hubbard RA, Johnson EE, Hsia R, Rutter CM. The Cumulative Risk of False-
Positiye Fecal Occult Blood Test after 10 Years of Colorectal Cancer Screenimg.
Cancer Epidemiol Biomarkers Prev 2018:22(9):1612-9. doi: 10.115871055-
9965.EPT-13-0254. PMITD: 23868091
Randel KR, Schult AL, Botteri E, Hoff G, Bretthauer M, Ursin G, Natvig E,
Berstad P Jergensen A, Sandvei PK, O]sen ME, Frigstad SO, Darre-Neesss O,
Norvard ER, Bolstad N, Kgrner H, Wibe A, Wensaas KA, de Lange T, Holme の.
Colorectal Camcer Screening With Repeated Fecal 1mmunochemncal Test Versus
Sigmoidoscopy: Baseline Results From a Randomized Trial. Gastroenterology,
2021:160(4):1085-96.e5. doi: 10.1053.gastro.2020.11.087. PMID 33227280
Grobbee EJ, van der Vlugt M, van Vuuren AJ, Stroobants AK, Mallant-Hent RC,
Lansdorp-Vogelaar 1, Bossuyt PMM, Kunpers EJ, Dekker E, Spaander MCW.
Diagnostic Yield of One-机me Colonoscopy vs One"Time Flexible SigmmoidoscoDy
vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests nm Colorectal
Cancer Screening. Chn Gastroenterol Hepatol. 2020:18(3):667-75.e1. doi:
10.1016j.cgh.2019.08.015. PMID 31419575
1nternationa1 Agency for Research on Cancer. Colorectal Cancer Screening. IARC
Handbooks of Cancer Prevention Volume 17.France: 1ARC Press. 2019.
IAvailable from:
https:/publications.iarc.fr/ publications/media/download5712/535af2201047a9b7
c7a63f47d736e0c1750e3c3fpdH
Marmot MG Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The
benefits and harms of breast cancer screening: an independent Yeview. Br J
Cancer. 2018:108(11):2205-40. don: 10.1038/bjc.2013.177. PMTDI 28744281
Luo D, Cambon AC, Wu D. Evaluating the long-term effect of FOBT in colorectal
cancer screening. Cancer pidemiol. 2012:36(1):e54-60. doi:
10.1016j.canep.2011.09.011. PMID: 22075536
Wieszczgy P Kaminski ME Lgberg M, Bugajski M, Bretthauer M, Kalager M.
Estimation of overdiagnosis in colorectal cancer screen1ing wth sigmoidoscopy
and faecal occult blood testing: comparison of simulation models. BMJ Open.
2021:11(4):e042158. do 10.1136/bmjopen-2020-042158. PMID 33853794
Chandan S. Facciorusso A, Yarra P Khan SR, Ramai D, Mohan BP, Kassab しL,
Bila1 M. Shaukat A. Colonoscopy-Related Adverse Events in Patents With
Abnormal Stool-Based Tests: A Systematic Review of Literature and Meta-
analysis of Outcomes. Am J Gastroenterol. 2022:117(3が881-93. doi:
10.14309/ajg.0000000000001614. PMID 35029161
62
27.
28.
29.
30.
91.
9グ2.
9.
Hubbard RA, Johnson EE, Hsia R, Rutter CM. The Cumulative Risk of False-
Positiye Fecal Occult Blood Test after 10 Years of Colorectal Cancer Screenimg.
Cancer Epidemiol Biomarkers Prev 2018:22(9):1612-9. doi: 10.115871055-
9965.EPT-13-0254. PMITD: 23868091
Randel KR, Schult AL, Botteri E, Hoff G, Bretthauer M, Ursin G, Natvig E,
Berstad P Jergensen A, Sandvei PK, O]sen ME, Frigstad SO, Darre-Neesss O,
Norvard ER, Bolstad N, Kgrner H, Wibe A, Wensaas KA, de Lange T, Holme の.
Colorectal Camcer Screening With Repeated Fecal 1mmunochemncal Test Versus
Sigmoidoscopy: Baseline Results From a Randomized Trial. Gastroenterology,
2021:160(4):1085-96.e5. doi: 10.1053.gastro.2020.11.087. PMID 33227280
Grobbee EJ, van der Vlugt M, van Vuuren AJ, Stroobants AK, Mallant-Hent RC,
Lansdorp-Vogelaar 1, Bossuyt PMM, Kunpers EJ, Dekker E, Spaander MCW.
Diagnostic Yield of One-机me Colonoscopy vs One"Time Flexible SigmmoidoscoDy
vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests nm Colorectal
Cancer Screening. Chn Gastroenterol Hepatol. 2020:18(3):667-75.e1. doi:
10.1016j.cgh.2019.08.015. PMID 31419575
1nternationa1 Agency for Research on Cancer. Colorectal Cancer Screening. IARC
Handbooks of Cancer Prevention Volume 17.France: 1ARC Press. 2019.
IAvailable from:
https:/publications.iarc.fr/ publications/media/download5712/535af2201047a9b7
c7a63f47d736e0c1750e3c3fpdH
Marmot MG Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The
benefits and harms of breast cancer screening: an independent Yeview. Br J
Cancer. 2018:108(11):2205-40. don: 10.1038/bjc.2013.177. PMTDI 28744281
Luo D, Cambon AC, Wu D. Evaluating the long-term effect of FOBT in colorectal
cancer screening. Cancer pidemiol. 2012:36(1):e54-60. doi:
10.1016j.canep.2011.09.011. PMID: 22075536
Wieszczgy P Kaminski ME Lgberg M, Bugajski M, Bretthauer M, Kalager M.
Estimation of overdiagnosis in colorectal cancer screen1ing wth sigmoidoscopy
and faecal occult blood testing: comparison of simulation models. BMJ Open.
2021:11(4):e042158. do 10.1136/bmjopen-2020-042158. PMID 33853794
Chandan S. Facciorusso A, Yarra P Khan SR, Ramai D, Mohan BP, Kassab しL,
Bila1 M. Shaukat A. Colonoscopy-Related Adverse Events in Patents With
Abnormal Stool-Based Tests: A Systematic Review of Literature and Meta-
analysis of Outcomes. Am J Gastroenterol. 2022:117(3が881-93. doi:
10.14309/ajg.0000000000001614. PMID 35029161
62